Southern Health and Social Care Trust

TOGETHER, IMPROVING CARE, TRANSFORMING LIVES

Information Governance Team

FOI 3588

13th February 2026

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Question: How many new patients were treated for any condition by the Trust's Dermatology Department in the latest 3-month period of October, November and December 2025 (or the latest 3 months available) with the treatments I have provided below?

If you are able to, could you please provide the split of new patients who received their treatment for Psoriasis.

Please can you define a "new patient" as a patient who is receiving any of the treatments listed below for the first time. If a patient received any of the below treatments in 2024 or previous years, they can be classed as a new patient for this period.

	Total Dermatology Department	Psoriasis
Adalimumab [Humira]		
Adalimumab [All Biosimilars]		
Etanercept [Enbrel]		
Etanercept [All Biosimilars]		
Infliximab [Remicade]		
Infliximab [All Biosimilars]		
Ustekinumab [Stelara]		
Ustekinumab [All Biosimilars]		
Apremilast [Otezla]		
Bimekizumab [Bimzelx]		
Brodalumab [Kyntheum]		
Certolizumab [Cimzia]		
Deucravacitinib [Sotyktu]		
Dimethyl Fumarate [Skilarence]		
Guselkumab [Tremfya]		
Ixekizumab [Taltz]		
Risankizumab [Skyrizi]		
Secukinumab [Cosentyx]		
Spesolimab [Spevigo]		
Tildrakizumab [Illumetri]		

Response:

Current patients as of 29/01/26	Total Dermatology Department	Psoriasis
Adalimumab [Humira]	**29**	**8**
Adalimumab [All Biosimilars]	**314**	**252**
Etanercept [Enbrel]	**0**	**0**
Etanercept [All Biosimilars]	**<5***	**<5***
Infliximab [Remicade]	**0**	**0**
Infliximab [All Biosimilars]	**10**	**<5**
Ustekinumab [Stelara]	**<5***	**<5***
Ustekinumab [All Biosimilars]	**22**	**22**
Apremilast [Otezla]	**0**	**0**
Bimekizumab [Bimzelx]	**14**	**14**
Brodalumab [Kyntheum]	**5**	**5**
Certolizumab [Cimzia]	**<5***	**<5***
Deucravacitinib [Sotyktu]	**0**	**0**
Dimethyl Fumarate [Skilarence]	**0**	**0**
Guselkumab [Tremfya]	**66**	**66**
Ixekizumab [Taltz]	**122**	**122**
Risankizumab [Skyrizi]	**123**	**123**
Secukinumab [Cosentyx]	**51**	**32**
Spesolimab [Spevigo]	**0**	**0**
Tildrakizumab [Illumetri]	**5**	**5**

*The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition, the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.

Email: Foi.Team@Southerntrust.hscni.net